Mahamaya Lifesciences informs BSE of MD and Executive Director interview in AgroPages 2026 India Focus Issue

Mahamaya Lifesciences has informed BSE that an interview with MD Krishnamurthy Ganesan and Executive Director Prashant Krishnamurthy appeared in AgroPages' 2026 India Focus Issue (September 2026 edition).

Fri 9 Oct 2026

FY2025-26 Revenue from operations

grew 24.5% to Rs. 328.87 crore

FY2025-26 EBITDA

grew 32.6% to Rs. 34.26 crore

FY2025-26 Profit after tax

grew 29.0% to Rs. 16.52 crore

What the company informed the exchange

Mahamaya Lifesciences has informed BSE that an interview featuring Mr. Krishnamurthy Ganesan, Managing Director, and Mr. Prashant Krishnamurthy, Executive Director, has been published in the 2026 India Focus Issue by AgroPages (September 2026 edition). A copy of the interview is enclosed with the intimation and is also made available on the company's website. The interview covers the company's operational progress, strategic growth initiatives and industry outlook.

Numbers discussed by management in the interview

• Revenue from operations grew 24.5% to Rs. 328.87 crore in FY2025-26
• EBITDA grew 32.6% to Rs. 34.26 crore
• Profit after tax grew 29.0% to Rs. 16.52 crore
• Net debt-to-equity improved to 0.74x during FY2025-26

Plans the management spoke about

• The company listed on the BSE SME platform in November 2025 and the IPO proceeds are being deployed across capacity expansion, research and development, debt reduction, working capital and general corporate purposes, with the largest allocation towards a new technical manufacturing facility at Dahej, Gujarat
• The Dahej project is being implemented in phases; the formulation expansion and the new R&D and pilot plant are targeted for completion by December 2026, and the technical manufacturing unit is expected to begin production by 2027
• The company has already received CIB&RC approvals for Technical Indigenous Manufacture (TIm) covering 25 molecules
• Planned domestic launches for FY2026-27 include ARUBA TWIN, MIRAI 500 and SPINOSTAR, while MAHAFLORA, MAHABASSIA and NEEMFORCE are planned in biological crop care
• Registered export presence includes Australia, Dominican Republic, Egypt, Turkey, Ethiopia, Oman, Taiwan, Jordan, Uganda and the UAE

How a retail investor can read this

The disclosure relates to the publication of an executive interview in a trade magazine. The figures above are as stated by the management in that interview, alongside their comments on the Dahej manufacturing roadmap, the brand and export pipeline and the global agrochemical environment. The shares are not the subject of any dealing, encumbrance or corporate action in this intimation.

Nothing here is a view, opinion or recommendation of ScoutQuest, its parent, directors or employees. ScoutQuest is a technology company: this page was assembled automatically from public sources using artificial intelligence, and may contain errors or omissions. Confirm everything against the original source before you act on it. Any use of this page is at your own risk, and neither ScoutQuest nor its parent, directors or employees accepts liability for it.